Effectiveness of cytoflavin in patients with high risk development of cerebrovascular diseases.

The aim of the study was to test the screening of the risk of developing cerebrovascular diseases and assess the effectiveness of cytoflavin in patients with a high risk of developing this pathology.

In addition to general clinical screening (determination of glucose and cholesterol levels in the blood, control of blood pressure and pulse, determination of body mass index), assessment of neurological status using an outpatient scale for assessing chronic cerebral ischemia A.I. Fedina and assessment of the level of cognitive functions — using the Mini-KOG test. Using screening, 64 people were examined, the average age of which was 50.5 ± 11.2 years. Surveyed with a high level of risk of developing pathology for the preventive purpose was prescribed Cytoflavin: 2 tablets. 2 times a day, a course of 30 days, with dynamic monitoring of the condition.

Screening for assessing the risk of developing cerebrovascular diseases has shown its effectiveness and allowed us to identify a group of patients at high risk of developing pathology. Patients of this group showed cerebral complaints, signs of asthenoneurotic syndrome and cognitive deficiency. The use of Cytoflavin helped to reduce the manifestations of asthenoneurotic syndrome and improve cognitive functions, had a positive effect on the concentration of attention, memory and thinking. However, the study was pilot in nature and its results can be used in planning further research.

1. Raimkulov B.N. Cerebrovascular Disorders (literature review). Vestnik KazNMU 2014;1(2):185–187. (in Russian)

2. Abdullaeva M.B., Raimova M.M., Majidova Y.N., Azimova N.M. Issues of multipurpose forecasting of ischemic strokes development. Global journal of Medicine and Medical science. 2019;7(8):505– 510.

3. Madzhidova Yo.N. Khodzhaeva D.T., Khajdarova D.K. The state of cerebral circulation in patients with moderate cognitive impairment in the presence of chronic cerebral ischemia. Nevrologiya i neyrokhirurgiya. Vostochnaya Evropa. 2015;4(28):75–80. (in Russian)

4. Neurology. National leadership. M., GEOTAR-Media, 2009 (in Russian)

5. Yuldasheva M.M., Madzhidova YO.N., Gafurov B.G., Nazarova Zh.А., Doronina O.B., Doronin B.M. Features of cerebral venous hemodynamics in acute cerebrovascular accidents. Prakticheskaya meditsina. 2019;7(17):111–117. (in Russian) DOI: 10.32000/2072-1757-2019-7-111-116.

6. Sacco R.L., Rundek T. Cerebrovascular disease. Curr. Opin. Neurol. 2012;25(1):1–4. DOI: 10.1097/WCO.0b013e32834f89b1.

7. Mashin V.V., Belova L.А., Saprygina L.V., Kravchenko M.А., Varakin Yu.Ya., Gnedovskaya E.V., Suslina Z.А. Risk factors for the development of cerebrovascular disease according to the screening of the middle-aged population of Ulyanovsk. Аnnaly klinicheskoj i ehksperimental’noj nevrologii. 2014;1(8):4–9. (in Russian)

8. Dolgova I.N., Kopenko T.А., Matevosyan M.А. Risk factors for cerebrovascular disease by gender. Mezhdunarodnyj studencheskij nauchnyj vestnik. 2016;4:65–66. (in Russian)

9. Merkin А.G., Kazhin V.А., Komarov А.N., Fonaryov А.V., Priyatel V.А., Nikiforov I.А. Prevention of cerebrovascular disease and cognitive impairment in psychiatric and neurological practice (literature review) Nevrologiya, nejropsikhiatriya, psikhosomatika. 2016;8(3):95–100 (in Russian) DOI: 10.14412/2074-2711-2016-3-95-100.

10. Belova L.А., Mashin V.V., Kolotik-Kameneva O.Yu., Belova N.V., Skuderi А., Аntignani P.L. The effect of therapy with the drug Cytoflavin on the structurally functional remodeling of cerebral vessels in various stages of hypertension. Zhurnal nevrologii i psikhiatrii im S.S. Korsakova. 2017;7(117):28– 35. (in Russian) DOI:.10.17116/jnevro20171177128-35.

11. Chutko L.S, Surushkina S.Yu., Yakovenko E.А., Rozhkova А.V., Volov M.B., Zhukovskaya N.V., Madzhidova Yo.N. Possibilities of using Cytoflavin in the treatment of cognitive and emotional disorders in patients with tension headaches. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 2019; 11(119):32–36. (in Russian) DOI: 10.17116/jnevro201911911132.

12. Smirnov А.V., Nesterova O.B., Golubev R.V. Succinic acid and its use in medicine. Part I. Succinic acid: a metabolite and metabolic regulator of the human body. Nefrologiya. 2014;18(2):33–41. (in Russian)

13. Mazin P.V., Sheshunov I.V., Mazina N.K. Meta-analytical assessment of the clinical efficacy of cytoflavin in neurological diseases. Zhurnal nevrologi i ipsikhiatrii im. S.S. Korsakova. 2017;3:30–39. (in Russian) DOI: 10.17116/jnevro20171173128-39.

14. Fedin A.I. Diagnosis and treatment of chronic cerebral ischemia. Consilium Medicum. 2016;2(18):8–12. (in Russian)

15. Kapil N., Datta Y.H., Alakbarova N., Bershad E., Selim M., Liebeskind D.S., Bachour O., Rao G.H.R., Divani A.A. Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke. Clin. Appl. Thromb. Hemost. 2017;23(4):301–318. DOI: 10.1177/1076029616660762. Epub 2016 Jul 26.